Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 9/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4966944 | 0.85 | DPP4 (0.54) | DPP4EPHX1RAB9A | |
| SCHEMBL4966724 | 0.84 | DPP4 (0.53) | DPP4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL4964917 | 0.84 | DPP4 (0.56) | DPP4EPHX1RAB9A | |
| SCHEMBL4963263 | 0.84 | DPP4 (0.53) | DPP4NPC1RAB9A | |
| SCHEMBL4963531 | 0.83 | DPP4 (0.56) | DPP4NPC1RAB9ACA1 | |
| SCHEMBL4966659 | 0.81 | DPP4 (0.50) | DPP4MMP2 | |
| SCHEMBL4968944 | 0.81 | DPP4 (0.53) | DPP4HDAC1HDAC8HDAC6NPC1 | |
| SCHEMBL4964297 | 0.80 | DPP4 (0.49) | DPP4EPHX1MMP2CA1ROCK2 | |
| SCHEMBL4966920 | 0.78 | DPP4 (0.50) | DPP4NPC1RAB9A | |
| SCHEMBL4968301 | 0.74 | DPP4 (0.46) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489088-B1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | NIPPON KAYAKU KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7348318-B2 | α-Amino-N-(diaminophosphinyl)lactam derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1489088-A1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | DNPEP, PEPD, ANPEP | DPP4 8/4885HDAC1 559/4885HDAC8 941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.